MGMT and astrocytoma (excluding glioblastoma): In summary, clinical management of both low‐grade and high‐grade paediatric/adult astrocytoma is governed by four key prognostic factors, age at diagnosis, MGMT methylation status, level of surgical intervention and use of chemotherapeutics such as TMZ.